Program Guide Decipher Certification and Training Registry (Decipher CTR)
|
|
- Peregrine Ralph Baldwin
- 5 years ago
- Views:
Transcription
1 Program Guide (Decipher CTR) This Program Guide provides a step- by- step overview of the operational aspects of the Decipher CTR, including how to (1) enroll as a healthcare provider and receive training on appropriate use of Decipher testing, (2) report any adverse events as a result of using Decipher (3) counsel and appropriately monitor your Medicare patients who have received Decipher testing. Because of the complicated nature of management decisions utilizing the Decipher assay and the potential for missing prostate cancer that could be salvaged with appropriate management at the appropriate time, testing must be furnished only by physicians who are enrolled in Decipher CTR program for Medicare Beneficiaries. The Decipher CTR program serves as a control to assure the appropriate selection of patients, compliance with management decisions and stringent follow up to ensure the benefits of the test outweigh its risks. The goals of the Decipher Certification and Training Program are as follows: To ensure that physicians understand the limitations of the test based on its validation through retrospective and heterogeneous patient populations, and To inform prescribers and patients on the safe- use conditions for Decipher, and To avoid missing clinically relevant development of metastatic prostate cancer or cancer related death with associated increased morbidity and mortality in Decipher low risk patients Decipher CTR Materials: Page A. Program Guide B. Training Package C. Sample Test Requisition Form (TRF) D. Healthcare Provider Enrollment (Form 1).. 11 E. Adverse Event Report (Form 2). 12 F. Patient Guide. 13 G. As the sponsor of Decipher CTR, GenomeDx Laboratory has committed to working with healthcare providers to ensure compliance with the registry requirements and to assist in gathering and reporting relevant data to the MolDX program within Palmetto GBA. Page 1 of 13
2 Program Guide (Decipher CTR) 1. Healthcare Provider Enrollment: A. Carefully review all Decipher CTR program documents. B. Complete necessary training by reviewing all the materials on DecipherCTR.com. C. Complete Healthcare Provider Enrollment form (page 11) and give to your GenomeDx representative, fax to GenomeDx Laboratory at (888) , to or complete form on DecipherCTR.com. 2. Decipher Testing: A. Decipher testing is covered by Medicare for intermediate and high- risk patients (post- radical prostatectomy), based on post- operative adverse pathology. B. The healthcare provider must be enrolled in the Decipher CTR and complete a Test Requisition Form to order Decipher for Medicare Beneficiaries. C. Patients should be appropriately counseled on: a. Benefits and risks of Decipher testing b. Decipher test results c. Need for additional follow- up and appropriate treatment options D. Report adverse outcomes for Medicare beneficiaries tested with Decipher, as required by the CTR. 3. Observational Data Collection/Reporting: A. Immediately report any distant metastases or prostate cancer related deaths in patients who were deemed low risk by the assay. B. A cumulative list will be sent to each enrolled healthcare provider every six months, showing their tested patients with low Decipher scores for use in checking for adverse events. C. Fully complete the Adverse Event Report (AER) Form (page 12) and fax to GenomeDx Laboratory at (888) or to client.service@genomedx.com. This form can also be downloaded on DecipherCTR.com. D. GenomeDx has support services for completing the AER. Contact GenomeDx or your Genomic Specialist to learn if our complimentary Pathology and Registry Manager Program may be right for you. 4. Program Compliance: A. The LCD(s) providing coverage for Decipher require healthcare providers to comply with all obligations of the Decipher CTR in order to maintain their certification. B. As sponsor of the Decipher CTR, GenomeDx may contact you from time- to- time to assure your continued compliance with the Decipher CTR and to provide any necessary ongoing provider and/or patient education. C. In the event of a continued failure to remain in compliance with the terms of the LCD and the Decipher CTR, GenomeDx is charged with taking appropriate measures to bring registered healthcare providers into compliance, including by instituting corrective actions up to and including de- certification. Page 2 of 13
3 Training Package (Decipher CTR) The Decipher Certification and Training Registry (CTR) has been established to enable Medicare coverage for eligible patients. Under Local Coverage Determination (LCD) DL35650, the Decipher test is considered reasonable and necessary for Medicare patients meeting identified coverage criteria and when ordered by a physician certified in the CTR. Section 1. Overview of Decipher Prostate Cancer Classifier Decipher Test Description The Decipher prostate cancer assay, a 22- biomarker expression signature using oligonucleotide microarray technology, interrogates 1.4 million RNA markers extracted from formalin fixed paraffin embedded (FFPE) prostate cancer tissue samples to assess a patient s risk for developing metastasis. The biomarkers that comprise the Decipher test include cell cycle progression, androgen signaling, cell adhesion, tumor cell motility, migration and immune evasion functions. The Decipher test provides an independent, individualized continuous estimate of risk of metastasis with higher sensitivity and specificity than the population based average risk currently available with clinical risk factors. Decipher Test Performance The clinical performance of this assay was assessed in several blinded, retrospective, clinical validation studies, enrolling more than 2000 patients. Validation studies included a wide diversity of patients with intermediate or high- risk prostate cancer who underwent radical prostatectomy (RP), many of whom subsequently developed metastatic disease. Decipher was developed using the metastasis end point, not an unreliable surrogate end point such as PSA recurrence. The test results have been shown to reclassify 8 out of 10 clinically high- risk men tested into lower or significantly elevated risk of metastatic disease progression. Section 2. Limitations of the Decipher Test There are heterogeneities in the patients included in the analysis both inside the trials and between trials. While a prospective trial with randomization and treatment based on the Decipher GC score would solve these biases, and recognizing that long- term prospective data would require 10 years or more, Noridian and the CMS MolDx contractor believe that clinical utility can be extrapolated from these robust retrospective clinical validity trials. The strength of this data is the consistency with which the Decipher GC score predicts metastasis across intermediate or high- risk patients who may or may not have had a BCR. Section 3. Important Safety Information When applying retrospective analysis to prospective treatment there is the fear that the treatment that normally would have been given is altered based on a test result. Consequently, education on the appropriate use of this test and resulting treatment outcomes must be clearly understood by ordering physicians. Section 4. Patient Eligibility Indications for Use Under Decipher LCD ID DL35650 The Decipher test is covered by Medicare only when the following clinical conditions are met: Page 3 of 13
4 A. Adjuvant setting (Post radical prostatectomy with adverse pathology): Patients who have undergone a RP within the previous 60 months and post prostatectomy is being considered for postoperative secondary therapy due to one or more cancer recurrence risk factors, AND a. Patient has achieved initial PSA nadir (defined as undetectable PSA) within 8 weeks, AND b. Patient has no evidence of distant metastasis, AND c. Patient has not received any neoadjuvant treatment prior to surgery, and d. Decipher GC is performed on a patient s RP specimen, AND e. Patient s surgical pathology report or medical records from RP have documented presence of adverse pathology defined as: i. Pathological stage T2 disease with a positive surgical margin, OR ii. Pathological stage T3 disease (e.g., extraprostatic extension, seminal vesicle invasion, bladder neck invasion), OR iii. High Preoperative PSA (e.g., PSA 20 ng/ml), OR iv. High Gleason score disease (e.g., Gleason 7 to 10 or Tertiary pattern 5), OR v. Perineural or lymphovascular invasion OR vi. Lymph node involvement B. Salvage setting (post PSA rise or biochemical recurrence after initial PSA nadir): Patient with prostate cancer who has undergone a RP and post prostatectomy experienced a PSA rise or biochemical recurrence (BCR), AND a. Patient achieved initial PSA nadir (defined as undetectable PSA) within 8 weeks of RP, AND b. Patient has no evidence of distant metastasis, AND c. Patient has not received any neoadjuvant or adjuvant treatment prior to PSA rise or BCR Section 5. Patient Management As part of the CTR requirements, to ensure the benefits of the Decipher test outweigh any risks, physicians should discuss risks and appropriate monitoring with their patient. Interpretation of Decipher Results At post- operative setting (Adjuvant): Decipher low risk patients can safely delay/defer treatment and avoid the adverse side effects of radiation treatment after radical prostatectomy. Decipher low risk patients have excellent outcomes with radical prostatectomy, with % five- year metastasis- free survival (95-100% ten- year cancer- specific survival), across multi- institutional cohorts treated with diverse postoperative treatment regimens (adjuvant or salvage or no treatment at all prior to metastatic onset) as reported in nine peer- reviewed publications 1-9. Decipher high risk patients can benefit from early radiation. Decipher high risk patients who received adjuvant radiation showed an 80% reduction in metastasis risk compared to salvage radiation 6. At post- BCR setting (Salvage): Post biochemical recurrence (BCR), Decipher low risk patients may be treated with salvage radiation alone, while Decipher high risk patients may require intensification of the treatment with a systemic therapy 8,9. Additionally, Decipher high risk patients who received early salvage RT (PSA 1 ng/ml) showed significantly better outcomes than those who received late salvage RT (PSA > 1 ng/ml) (10- year metastasis 15% vs 35%, p=0.031) 9. Page 4 of 13
5 Safe Use The Decipher test does not detract from your physician s treatment recommendations and other clinical and pathological indicators. Regardless of your treatment decision, it is crucial that you continue to monitor your prostate cancer closely by maintaining follow- up appointments regularly. Section 6. Decipher Peer Reviewed Scientific Evidence Decipher Clinical validity The Decipher test was developed using archived formalin- fixed paraffin embedded (FFPE) blocks of tumors selected from 621 patients that had undergone a radical prostatectomy (RP) at the Mayo Clinic Comprehensive Cancer Centre between the years , providing a median of 18 years follow- up 1. The endpoint used for the discovery was clinical metastasis, not a surrogate endpoint such as BCR. Moreover, the patients that developed metastasis after BCR were compared to two control groups of patients, the first group with BCR- only but no metastasis (with at least 5 years of follow up) and the second group without BCR and no evidence of disease (with at least 7 years of follow up). The premise of using metastasis as an endpoint in the development of Decipher was critical to increasing the specificity of the test for identifying patients truly at risk of developing metastasis. This is because not everyone who experiences BCR develops metastasis, as discussed in a recently published study (Alshalalfa et al. BJU Intl, 2015) that further supports using clinical and genomic analysis that BCR is a poor, non- specific surrogate for lethal disease. In addition to the well- defined study design, the comprehensive transcriptomic- wide survey for the most prognostic markers, which led to the identification of the 22 Decipher markers, also played an important role in improving the robustness of the test. These markers represent a network of biological pathways associated with tumor progression including cell proliferation, cell adhesion and motility, immune system modulation, cell cycle progression, and androgen signaling. Also, nearly half of the Decipher markers are non- coding RNA highlighting their pivotal role in prostate cancer progression (Alshalalfa et al. Biology of the Cell, 2015). Subsequent to the discovery and the initial validation in the Mayo cohort, Decipher was clinically validated to predict the probability of metastasis after surgery in multiple patient cohorts with postoperative high- risk features, such as pathological stage pt2 with positive margins or pt3 disease or a rising serum prostate- specific antigen (PSA) as reported in nine published independent validation studies Decipher test showed consistent performance in the indicated testing population (87-100% of studied patients had adverse pathology or PSA rise) with over 2,000 patients studied in prospectively- designed blinded evaluations by leading academic and NCI- designated cancer centers (Mayo Clinic, Thomas Jefferson University, Johns Hopkins University and Cleveland Clinic) and outperformed clinical variables currently used in standard practice such as preoperative PSA and Gleason score. The Decipher test provided independent individualized information for a patient s risk assessment after surgery and stratified the indicated population. Therefore, identifying those patients with good prognosis who are unlikely to benefit from additional therapeutic intervention after surgery, and additionally identifying patients most likely to benefit from adjuvant radiation therapy as opposed to delayed (salvage) therapy. In summary, the eight validation studies have demonstrated that: Decipher low risk patients can safely delay/defer treatment and avoid the adverse side effects of radiation treatment after radical prostatectomy. Page 5 of 13
6 o Decipher low risk patients have excellent outcomes with radical prostatectomy, with % five- year metastasis- free survival (95-100% ten- year cancer- specific survival), across multi- institutional cohorts treated with diverse postoperative treatment regimens (adjuvant or salvage or no treatment at all prior to metastatic onset) as reported in nine peer- reviewed publications 1-9. o Post biochemical recurrence (BCR), salvage therapy with no concurrent hormones, was sufficient in Decipher low risk patients 8,9. Decipher high risk patients can benefit from early radiation. o Decipher high risk patients who received adjuvant radiation showed an 80% reduction in metastasis risk compared to salvage radiation 6. o Post biochemical recurrence (BCR), Decipher high risk patients may require intensification of the treatment with a systemic therapy, and those who received early salvage RT showed significantly better outcomes than those who received late salvage RT (10- year metastasis 15% vs 35%, p=0.031) 8,9. Decipher Clinical Utility Five published studies of clinical management investigated the influence of the Decipher test on physicians post- surgery treatment decisions for the intended use population - postoperative high- risk prostate cancer patients The Decipher test was consistently shown to influence treatment decisions of over 120 physicians from 60 tertiary and community cancer centers across the United States. Overall, 34% changed their treatment decisions after reviewing Decipher test results, redirecting postoperative treatments for Decipher high- risk and observation for Decipher low- risk patients. In addition, a decision analysis study showed in two independent cohorts of high- risk men that compared to standard care, Decipher - guided treatment decisions led to a 12% relative increase in 5- year recurrence- free survival (16% at 10 years) and a 4% relative reduction in the 5- year probability of metastatic disease or death. Importantly, these gains in survival are achieved with overall lower burden of postoperative therapy in the population. In summary, the five clinical utility studies have demonstrated that: Decipher reclassifies 60% of clinically high risk men to genomic low risk men who by current clinical practice guidelines are ALL recommended to receive 6-8 weeks of for costly and toxic intensity- modulated radiation therapy Compared to the average clinical risk of metastasis, Decipher low risk patients (60% of men) had significantly lower than average clinical risk (~2- times lower) whereas Decipher high risk patients (20% of men) had significantly higher than average clinical risk (>3- times higher). Decipher- based treatment models consistently showed a higher net benefit (balance of benefits and harms) on patient outcome for postoperative treatment decision- making compared with pathological risk models (i.e., Gleason, CAPRA- S, Eggener, Kattan and Stephenson nomograms) or clinical scenarios where no risk prediction model would be used (i.e. treat all or treat none with adjuvant radiation) 2-8. Decipher test results transform physician decision- making o Decipher low risk (~60% of men tested) 90% opt for active observation (e.g., PSA monitoring) instead of additional therapy. o Decipher high risk (~20% of men tested) 64% recommend adjuvant radiation for these patients most at risk and consequently most likely to benefit. The most impactful aspect of clinical utility for patients getting the Decipher test is around optimal timing of postoperative treatment, enabling physicians to decide whether it can be delayed/deferred or avoided altogether and when is it most beneficial. Consequently, as reported in the clinical validity studies, Decipher- based treatment models consistently showed a higher net benefit (balance of benefits Page 6 of 13
7 and harms) on patient outcome across a wide range of risk compared with scenarios in which clinical only models (i.e. CAPRA- S and Stephenson nomograms) or no prediction model would be used for a postoperative radiation therapy treatment decision (i.e. treat all or treat none). Decision analytic outcomes modeling further shows that Decipher directed individualized care is associated with a 16% relative increase in the 10- year recurrence- free survival probability 13. References 1. Erho, N., et al., Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One, (6): p. e Karnes, R.J., et al., Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. The Journal of urology, : p Klein, E.A., et al., A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node- negative High- risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy. European Urology, (4): Cooperberg, M.R., et al., Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High- risk Prostatectomy Cohort. European Urology, (2):p Den, R.B., et al., Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys, (5): p Robert B. Den, K.Y., Edouard J. Trabulsi, Firas Abdollah, Voleak Choeurng, Felix Y. Feng, Adam P. Dicker, Costas D. Lallas, Leonard G. Gomella, Elai Davicioni and R. Jeffrey Karnes, A genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. Journal of Clinical Oncology, : Ross AE, Yousefi K, Trock B, Choeurng, V., Lam, L.L.C., Fedor, H.L., Ghadessi, M., Buerki, C. Glavaris, S., Sundi, D., Tosoian, J., Han, M., Humphreys, E.B., Partin, A.W., Netto, G.J., Davicioni, E. Schaeffer, E.M., Tissue Based Genomics Augment Post- Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High- Risk Men. European Urology 2015; doi: /j.eururo Ross, A.E., Feng, F.Y., Ghadessi, M., Erho, N., Crisan, A., Buerki, C., Sundi, D., Mitra, A.P., Vergara, I.A., Thompson, D.J.S., Triche, T.J., Davicioni, E., Bergstralh, E.J., Jenkins, R.B., Karnes, R.J. and Schaeffer, E.M., A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate cancer and prostatic diseases 2014; 17(1): Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam L, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah N, Feng FY, Davicioni E, Dicker AP, Abodllah F, Karnes RJ and Den RB, Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy. Journal of Clinical Oncology 33, 2015 (suppl; abstr 5016) 10. Yamoah, K., Johnson, M.H., Choeurng, V., Faisal, F.A., Yousefi, K., Haddad, Z., Ross, A.E., Alshalafa, M., Den, R., Lal, P., Feldman, M., Dicker, A.P., Klein, E.A., Davicioni, E.,Rebbeck, T.R., Schaeffer, E.M., A novel biomarker signature which may predict aggressive disease in African- American men with prostate cancer. Journal of Clinical Oncology 2015; doi: /JCO Page 7 of 13
8 11. Badani, K.K., Thompson, D.J.S., Buerki, C., Davicioni, E., Garrison, J., Ghadessi, M., Mitra, A.P., Wood, P.J., and Hornberger, J., Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013; 4(4): Michalopolous, S.N., Kella, N, Payne, R., Yohannes, P., Singh, A., Hettinger, C., Yousefi, K., and Hornberger, J., Influence of a genomic classifier on post- operative treatment decisions in high- risk prostate cancer patients: results from the PRO- ACT study. Curr Med Res Opin 2014; 30(8): Lobo, J.M., Dicker, A.P., Buerki, C., Davicioni, E., Karnes, R.J., Jenkins, R.B., Patel, N., Den, R.B., and Showalter, T.N., Evaluating clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PLoS One Apr 2;10(3):e doi: /journal.pone ecollection Badani, K.K., Thompson, D.J., Brown, G., Holmes, D., Kella, N., Albala, D., Singh, A., Buerki, C., Davicioni, E., and Hornberger, J., Effect of a genomic classifier test on clinical practice decisions for patients with high- risk prostate cancer after surgery. British Journal of Urology Intl 2014; 115(3): Nguyen, P., Shin, H., Yousefi, K., Thompson, D.J., Hornberger, J., Hyatt, A.S., Badani, K.K., Morgan, T., and Feng, Y.F., Impact of a Genomic Classifier of Metastatic Risk on Post- Prostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology 2015; 86(1): Featured on the cover of Urology July Page 8 of 13
9 PATIENT INFORMATION Patient Name (Last, First) A Barcode ORDERING PHYSICIAN INFORMATION Ordering Physician Name GenomeDx Biosciences CLIA License # 05D DOB (MM/DD/YYYY) MRN / Patient ID# NPI Address City State ZIP Telephone Cell CLINICAL HISTORY -Please check all that apply: Please provide pathology report Familial History of Prostate Cancer Man of African Heritage PATHOLOGY FEATURES - Please check all that apply: Pre-Operative PSA ( 20ng/mL) Extraprostatic Extension High Gleason Score ( 7) Seminal Vesicle Invasion Tertiary Gleason 5 Bladder Neck Invasion Perineural or Lymphovascular Invasion Lymph Node Involvement Positive Surgical Margins Rising PSA or Biochemical Recurrence Other Date of Prostatectomy (MM/DD/YYYY) Pre-Operative PSAValue ng/ml Gleason Score + Please complete Laboratory and Telephone in Section G Pre-Decipher test treatment recommendations Contact Name Contact Practice Name Address City State ZIP Telephone Special Requests: Fax SIGNATURE OF AUTHORIZED PERSONNEL: Your signature constitutes a request for the Decipher Prostate Cancer Classifier if the clinical and pathology diagnosis meets Decipher testing criteria. In addition, your signature constitutes a Certification of Medical Necessity. As part of the Decipher testing, additional genomic information as part of the Decipher GRID will be collected and provided upon request for research use only (RUO). Please read reverse side for details. Check here for a Decipher GRID Analysis Report, in addition to the Decipher Genomic Classifier report. Note that the Decipher GRID Analysis Report can be requested at any time. For Medicare Beneficiaries: I further certify that I have completed requisite training and have enrolled in the GenomeDx CTR program. The Medicare patient eligibility criteria is provided on the back side of this form. Observation with PSA Adjuvant or Early Salvage RT Please include medical notes RT + ADT Other Signature Print Name Date BILLING: please provide a copy of both sides of the insurance card(s) Billing Type: Private Insurance Not Insured / Self-Pay Medicare - Date of Discharge (MM/DD/YYYY) ICD-9/10 CODE(S): Please list all ICD-10 codes that apply to this patient. Coding should always be based on what has been documented in the patient s medical record. If a diagnosis code cannot be supported by the patient s medical record, then the code should not be used for ordering laboratory services. See reverse for list of possible codes. Option A: BILL TO INSURANCE Primary Insurance Name of Insured Subscriber ID # Group # Secondary Insurance Name of Insured Patient has had neoadjuvant therapy prior to surgery Subscriber ID # Group # Option B: BILL TO PATIENT 185/C61 Neoplasm of the Prostate Other: Other: Relationship to Patient Relationship to Patient ADDITIONAL PHYSICIAN REQUIRING RESULTS Name Telephone Fax PATHOLOGY INFORMATION: Laboratory Telephone Fax Submitting Pathologist Specimen ID # Date Pulled from Archive Blocks should be returned to the address below: Address City State ZIP Telephone Fax NOTES FOR LAB USE ONLY: G PLEASE FAX REQUISITION TO: OR TO: orders@genomedx.com Science Center Dr., Suite 240 San Diego, CA Client.service@genomedx.com Page 9 of 13
10 . MolDX LCD ID: DL35650 Decipher Requisition Form Instructions A. Patient Information Enter patient name and date of birth as they are required to perform the test. Patient address information is necessary for billing purposes. If you are providing patient information with a copy of a face sheet, you must still enter patient name and date of birth. B. Clinical History & Pathologic Features Please provide the requested clinical history and a copy of the surgical pathology report. Please identify the patient s clinical and pathological features as well as the pre Decipher test treatment recommendation. Known risk factors for prostate cancer metastasis include; a familial history of prostate cancer (i.e., brother, father or first degree relative), African heritage, preoperative PSA 20 ng/ml, Gleason score 7, tertiary Gleason 5, perineural or lymphovascular invasion, positive surgical margins, extraprostatic extension, seminal vesical involvement, bladder neck invasion, lymph node involvement, rising PSA or biochemical recurrence. C. Billing Information Please indicate the billing type. If patient has Medicare, please enter the date of discharge. The ICD-9/10 diagnosis codes must be defined for the most detailed level of specificity available. Please refer to your ICD-9/10 manual for a complete listing. 185/C61 MALIG NEO PROSTATE 233.4/D07.5 CA IN SITU PROSTATE /N39.3 STRESS INCONTINENCE MALE /N40.1 BPH W OBSTRUCT OR LOWER UT SYMPTOM /N40.0 BPH WO OBSTRUCT OR LOWER UT SYMPTOM 229.0/D36.0 BENIGN NEO LYMPH NODES 272.4/E78.4 OTH/UNS HYPERLIPIDEMIA 272.4/E78.5 HYPERLIPIDEMIA, UNSPECIFIED 394.9/105.8 OTH/UNS MITRAL VALVE DISEASES /N13.9 URINARY OBSTRUCTION UNSPEC 601.4/N51 PROSTATITIS IN DISEASE 601.9/N41.9 UNS PROSTATITIS V76.44/Z12.5 SCREEN MAL NEO PROSTATE Check/select the party responsible for payment of the Decipher test. GenomeDx will submit claims to all private insurance, Medicare and other government plans for insured patients. OPTION A - To bill private insurance, Medicare, Medicaid or other insurance: Please provide a clear copy of the front and back of the primary insurance card. If the patient has secondary insurance, provide a clear copy of the front and back of the secondary insurance card. OPTION B - For patient payment: GenomeDx Client Services and Customer Support will contact patient prior to specimen processing. Medicare The Decipher Beneficiaries assay is covered by Eligibility Medicare only when Indication the following clinical conditions are met: for Use Under GenomeDx LCD ID LL##### Medicare Beneficiaries Eligibility Indications for Use Under Decipher LCD ID L35650 Patient has no evidence of distant metastasis, and Patient has achieved initial PSA nadir (defined as undetectable PSA) within 4-6 weeks, and Patient has not received any neoadjuvant treatment prior to surgery, and Pathological stage T2 disease with a positive surgical margin, or Pathological stage T3 disease (e.g., extraprostatic extension, seminal vesicle invasion, bladder neck invasion), or High Preoperative PSA (e.g., PSA 20 ng/ml), or High Gleason score disease (e.g., Gleason 7 to 10 or Tertiary Gleason pattern 5), or Perineural, lymphovascular invasion, or Lymph node involvement or Rising PSA or Biochemical Recurrence D. Ordering Physician Information Enter physician name, NPI, address and contact details for the ordering physician. Verify address information. Provide correct information if missing or incorrect. Special Requests must be entered. Provide additional physician details should a duplicate report be required. E. Signature of Ordering Physician Ensure test request form is signed and dated. Please fax the test requisition form directly to GenomeDx Biosciences Laboratory on the toll-free fax number provided. ATTENTION: The signature constitutes a certification of the following: a. With respect to tests reimbursed by Medicare, Medicaid or other third party payers, the Decipher test is medically necessary and the results will be used in addition to other clinical information in the management of the patient s condition. b. If the ordering physician is not the treating physician, the ordering physician confirms that the treating physician has deemed the Decipher test medically necessary and the results will be used in addition to other clinical information in the management of the patient s condition. F. Additional Physicians Requiring Results If you would like GenomeDx to send Decipher test results to an additional physician, please fill out the physician s contact information. If you would like to send a patient report to another physician who is responsible for the care of this patient, enter the contact information in this section. Patient Reports cannot be sent to P.O. Boxes. G. Pathology Information: to be completed by pathology Enter pathologist name, specimen information, and pathology laboratory contact information. The requested information is required in order to run the Decipher test. Ensure a copy of the surgical pathology report is provided along with the requisition form. Decipher Description Decipher uses oligonucleotide microarrays to measure 22 RNA expression biomarkers, extracted from formalin-fixed paraffin-embedded (FFPE) primary prostate adenocarcinoma specimens, to derive a 5 year probability of clinical metastasis after radical prostatectomy. The Decipher probabilities range from 0 100%. Decipher is intended for use by the physician and patient as an adjunct to conventional clinical and pathological variables and models currently used for determining prognosis and treatment of prostate cancer patients after radical prostatectomy. Decipher is intended for use in patients with high-risk postoperative features to impact treatment decision making. For more information, visit DecipherTest.com. Decipher GRID Description The Decipher technology platform allows for the collection of up to 1.4 million biomarkers for each patient who has Decipher testing performed. As an enhanced service to GenomeDx clients, the additional information is securely stored in the Decipher GRID, the largest clinicallyannotated genomic expression database in urologic cancer. Upon request of the ordering physician, GenomeDx will provide the patient s GRID information for RUO (research use only) purposes. The GRID Analysis Report, a component of Decipher GRID, reports on the expression of multiple common molecular subtypes of prostate cancer, androgen signaling, proliferation, neuroendocrine disease, and immune checkpoint disease biomarkers. For more information, visit DecipherGrid.com. Contact Information Phone: Client Services & Customer Support: US Toll-Free Fax: Web: GenomeDx.com / DecipherTest.com Address: GenomeDx Biosciences Laboratory, Science Center Drive, Suite 240, San Diego, CA The GenomeDx Biosciences Laboratory is licensed for high complexity testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Page 10 of 13
11 Page 11 of 13
12 Page 12 of 13 Page 12 of 13
13 Contact the GenomeDx Patient Care Team at (toll-free) or MolDX LCD ID: DL35650 MolDx LCD ID: L35868 Patient Guide Decipher Certification and Training Registry (Decipher CTR) Instructions for Healthcare Providers: Provide a copy of this Guide or the Decipher Patient Brochure upon counseling Medicare patients. Visit to download the Decipher Patient Brochure. % Do I need more therapy after my prostate has been removed? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your care Decipher Prostate Cancer Classifier Patient Guide for Medicare Beneficiaries Introduction:+This%guide%describes%the%intended%use%of%the%Decipher%test%for%Medicare% beneficiaries%with%adverse%pathology%post9surgery.%knowing%your%probability%of%prostate% cancer%recurrence%and%metastasis%after%surgery%based%on%the%genomics%of%your%cancer%can% help%you%and%your%doctor%make%important%decisions%about%your%care.% % Purpose:+Decipher %is%a%transformative%genomic%test%that%informs%decisions%about%the%course%of% treatment%for%men%after%prostate%surgery.%for%patients,%this%means%a%personalized%assessment%of% your%risk%of%prostate%cancer%recurrence%after%prostatectomy.%decipher%measures%the%activity%of% certain%genes%in%the%tumor%that%are%known%to%be%involved%in%the%development%and%progression%of% prostate%cancer%to%tell%you%more%about%how%your%cancer%may%behave%and%develop.%the%test% analyzes%a%small%tissue%sample%that%was%removed%during%surgery%and%is%routinely%archived%or%stored% by%the%pathology%laboratory.%no%additional%procedures%are%required.% % Test+Results:+Patients%are%identified%as%High,%Average%or%Low%Decipher%risk%based%on%their%predicted% probability%of%developing%metastasis.%%after%prostatectomy,%decipher%high9risk%patients%may% benefit%from%early%radiation%and%decipher%low%risk%patients%may%be%managed%safely%with% observation%until%psa%rise,%if%any.%%decipher%high%risk%patients%with%detectable%psa%rise%may%require% intensification%of%therapy%beyond%radiation%and%decipher%low%risk%patients%have%excellent% prognosis%with%late%radiation%therapy%and%may%avoid%concurrent%hormone%therapy.% + Treatment+Plan:+The%Decipher%test%is%an%important%tool%that%can%help%tell%you%how%likely%your%cancer% is%to%spread%(metastasize)%beyond%your%prostate%after%surgery.%it%is%important%to%understand%all%of% your%options%before%making%any%decision%about%your%prostate%cancer%care%after%radical% prostatectomy.%you%and%your%doctor%have%a%lot%to%consider%before%choosing%a%treatment%plan%that%is% right%for%you.%your%physician s%treatment%plan%may%be%based%on%a%number%of%factors%such%as%your% level%of%risk,%your%personal%circumstances,%and%your%own%desires%for%additional%therapy%based%on% risks%and%benefits.% % Safe+Use+Conditions:+The%Decipher%test%does%not%detract%from%your%physician s%treatment% recommendations%and%other%clinical%and%pathological%indicators.%regardless%of%your%treatment% decision,%it%is%crucial%that%you%continue%to%monitor%your%prostate%cancer%closely%by%maintaining% follow9up%appointments%regularly.% Page 13 of 13
Providing Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationRadical prostate surgery?
Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationEvaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality
Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality Kathryn L. Pellegrini, Emory University Martin Sanda, Emory University Dattatraya Patil, Emory
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationReconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era
For reprint orders, please contact: reprints@futuremedicine.com Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era Aim: We developed a decision analysis framework
More informationMultigene Testing in Prostate Cancer Risk Stratification
Multigene Testing in Prostate Cancer Risk Stratification Ashley Ross, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Objectives Briefly review relevant molecular biology of localized
More informationMolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
MolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer Noridian Healthcare Solutions, LLC Please Note: This is a Proposed LCD. Proposed LCDs are works in progress
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationKEYWORDS: adjuvant therapy, Decipher, decisional conflict, prostate cancer, prostatectomy, quality of life, salvage therapy.
Decipher Test Impacts Decision Making Among Patients Considering Adjuvant and Salvage Treatment After Radical Prostatectomy: Interim Results From the Multicenter Prospective PRO-IMPACT Study John L. Gore,
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): MolDX: ConfirmMDx Epigenetic Molecular Assay (L36328) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationRadiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices
Original original research Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices Michel Zimmermann, MD; * Daniel Taussky,
More informationFDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer.
Clinical Policy: (Firmagon) Reference Number: CP.PHAR.170 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationCorporate Medical Policy
Corporate Medical Policy Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_and_protein_biomarkers_for_diagnosis_and_risk_assessment_of_prostate_cancer
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationTABLE OF CONTENTS. Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma. Analytical Validity
Clinical Dossier TABLE OF CONTENTS Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma 1 2 3 Analytical Validity 4 Clinical Validity 4 Clinical Utility 7 Medicare
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationTITLE: High throughput sequencing of germline and tumor from men with early-onset, metastatic prostate cancer
AWARD NUMBER: W81XWH-13-1-0371 TITLE: High throughput sequencing of germline and tumor from men with early-onset, metastatic prostate cancer PRINCIPAL INVESTIGATOR: A. Cooney, M.D. CONTRACTING ORGANIZATION:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationAre Payers Getting Tougher? Essential Insights on How to Smooth Acceptance of New Genetic Tests
Are Payers Getting Tougher? Essential Insights on How to Smooth Acceptance of New Genetic Tests Jacqueline Huang Senior Associate Reimbursement Policy and Government Affairs Objectives Learn how payers
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationMedication Prior Authorization Form
Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide
More informationHow will new biomarkers change prostate cancer management
How will new biomarkers change prostate cancer management Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics BAUS Section of Oncology Annual Meeting Cardiff, UK 15 November
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationGENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT
CANCER MANAGEMENT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationAbstract: Background: Only a minority of prostate cancer patients with adverse pathology
/ Oncotarget, April, Vol.4, No 4 Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group Ketan Badani
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0546 TITLE: Assessing EphA2 and Ephrin-A as Novel Diagnostic and Prognostic Biomarkers of Prostate Cancer PRINCIPAL INVESTIGATOR: Carvell Tran Nguyen, MD PhD CONTRACTING ORGANIZATION:
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationMP Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Medical Policy MP 2.04.111 BCBSA Ref. Policy: 2.04.111 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section: Medicine Related Policies 2.04.33 Genetic and Protein Biomarkers for the Diagnosis and
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationGene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Policy Number: 2.04.111 Last Review: 04/2018 Origination: 04/2014 Next Review: 04/2019 Policy Blue Cross and Blue Shield
More informationFOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey
FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER Discover a test that can help you on your treatment journey Jim G. Oncotype DX GPS patient navigating prostate cancer since 2014 Not all prostate
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationDate of preparation- January 2018 Janssen Biotech, Inc /18 em Reporter s guide to. prostate cancer
Date of preparation- January 2018 Janssen Biotech, Inc. 2018 02/18 em-01856 Reporter s guide to prostate cancer What is the prostate? The prostate is a gland located below the bladder, wrapped around the
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.04.33 Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Gene Expression Profiling
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationIllumina Clinical Services Laboratory
Illumina Clinical Services Laboratory Illumina, Inc. 5200 Illumina Way San Diego, CA 92122, USA Phone: 858.736.8080 Fax: 858.255.5285 everygenome@illumina.com CLIA Certificate No.: 05D1092911 Illumina
More informationNotification for Outpatient Injectable Chemotherapy for Medicare Advantage Plans Frequently Asked Questions
Notification for Outpatient Injectable Chemotherapy for Medicare Advantage Plans Frequently Asked Questions Key Points Physicians and facilities are required to submit notification to UnitedHealthcare
More informationThe Selenium and Vitamin E Prevention Trial
The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationSystems Pathology in Prostate Cancer
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDiscovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy
Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy Anirban P. Mitra, M.D., Ph.D. Center for Personalized Medicine University of Southern California
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationDevelopment and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
Personalized Medicine and Imaging Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy R. Jeffrey Karnes 1, Vidit
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationNational Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms
Form (NOPR) F-18 Fluoride PET Case Report Forms Version Date Patient Information Sheet 06/17/10 (Spanish translation available at: http://www.cancerpetregistry.org/pdf/patient_info_spanish.pdf) Interpreting
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More information4Kscore. A Precision Test for Risk of Aggressive Prostate Cancer
4Kscore A Precision Test for Risk of Aggressive Prostate Cancer How to Evaluate Risk for Prostate Cancer? PSA is a good screening tool But abnormal PSA leads to over 1 million prostate biopsies each year
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More information2012 EHR Donation Program ELIGIBILITY FORM
2012 EHR Donation Program ELIGIBILITY FORM Doing business with HealthTronics Lab Solutions is NOT a condition of receiving a donation. PROGRAM In good faith with the community s commitment to promote the
More informationClinical Policy: Robotic Surgery Reference Number: CP.MP. 207
Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207 Effective Date: 03/05 Last Review Date: 10/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationA Genomic Approach to Active Surveillance
A Genomic Approach to Active Surveillance Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Cleveland Clinic Disclosures
More information